Nurix Therapeutics Inc
NRIX
Get informed when a big investor buys or sells
+ Follow
Share Statistics
| Market cap | $1.52 Billion |
|---|---|
| Enterprise Value | $1.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.05 |
| Beta | 1.87 |
| Outstanding Shares | 110,071,668 |
Return
| Return on Equity | -61.40% |
|---|---|
| Return on Assets | -46.42% |
| Return on Invested Capital | -56.16% |
Valuation & Multiples
| P/E Ratio | -6.54 |
|---|---|
| PEG | -11.96 |
| Price to Sales | - |
| Price to Book Ratio | 4.66 |
| Enterprise Value to Revenue | 21.28 |
| Enterprise Value to EBIT | -5 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0575▼ 29.96% |
|---|---|
| Total Calls | 250,600▲ 7.28% |
| Total Puts | 14,400▼ 82.73% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.32%▼ 24.55% |
|---|---|
| Total Invested | $1.81B▼ 15.69% |
| Investors Holding | 197▲ 11.00% |
ESG Score
No data
About Nurix Therapeutics Inc
2,020 employeesNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...
Relevant Senate Committees
Controls Medicare and Medicaid reimbursement policy; pricing and coverage decisions for oncology drugs are critical to the eventual commercial success of Nurix's pipeline.
Determines the specific funding levels for the FDA and NIH, which directly affects the speed of drug reviews and the volume of early-stage research grants available.
This committee directly oversees the FDA and NIH, regulating the entire drug approval process and federal funding for basic biomedical research.
This committee oversees intellectual property and patent law, which is the foundational value driver for Nurix's proprietary platform and drug candidates.